Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Atlantic American Corporation (AAME): Is a +25% Move to $1.50 in Sight?

Atlantic American Corporation (AAME): Is a +25% Move to $1.50 in Sight?

Key Takeaways

  • The $1.50 target used here is not an analyst consensus; no credible, current Wall Street price targets exist for AAME. It reflects a conservative valuation-re-rating scenario grounded in the stock's deep discount to book value.
  • Shares were trading near $1.20–$1.22, so reaching $1.50 implies upside of roughly 23–25%, a substantial move for a micro-cap.
  • The stock trades at about 0.21 times book value (P/B, or price-to-book ratio) and roughly 4.4 times trailing earnings, with a small dividend and roughly $210 million in trailing revenue.
  • The strongest supporting factors are the valuation discount, improved 2025 profitability, and a healthy cash position.
  • The biggest risks are a pending Nasdaq delisting process tied to delayed financial filings and extremely thin, illiquid trading.
  • For more detail, visit Tickeron's Major News and Today's Price Move pages, review the Forecast page, and check the Earnings page before making any decision.
  • You can also explore Trending AI Robots to see AI-driven strategies monitoring this and similar tickers.

How the $1.50 Target Was Established

Unlike large-cap names, AAME has essentially no active, attributable analyst price targets. Major aggregators show the one-year price target as unavailable, and the only published rating trail traces to rating services rather than equity research desks with formal targets. Because there is no usable analyst consensus, the $1.50 figure is a fallback objective drawn from publicly discussed valuation reasoning rather than a Wall Street forecast.

The core argument is the gap between the stock's market value and its balance sheet. Reported book value per share is roughly $5.90, yet the shares trade near $1.20, or about 0.21 times book. Even a partial re-rating to a still deeply discounted 0.25 times book would imply a price near $1.50. The 50-day moving average near $1.64 and the 200-day moving average near $1.87 sit above that level, making $1.50 a conservative first recovery milestone rather than a return to prior highs. This is a valuation-driven scenario, not a guarantee, and it should not be read as a published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

With the stock near $1.20, reaching $1.50 requires a gain of roughly 25%, which qualifies as a substantial move for a thinly traded micro-cap. The shares have been volatile, trading between about $1.01 and $3.22 over the past year, and are down more than 50% for 2026.

The company generated trailing revenue near $210 million with net income around $5.6 million and EPS (earnings per share) of about $0.28, implying a P/E (price-to-earnings ratio) near 4.4. A path toward $1.50 would most plausibly run through restored investor confidence: completing overdue financial reports, resolving the Nasdaq listing process, and convincing the market that reported book value is reliable. Until those conditions improve, the discount to book may persist or widen.

What Could Support a Move Toward the Target

  • Valuation. A P/B near 0.21 and a single-digit P/E suggest the market is pricing in considerable distress, leaving room for re-rating if confidence returns.
  • Improved 2025 fundamentals. Third-party commentary points to stronger profitability, cash flow, and a cleaner balance sheet in 2025.
  • Liquidity. Reported cash and equivalents near $43.6 million provide a buffer relative to the company's small equity value.
  • Regaining compliance. The company filed its overdue 2025 Form 10-K in October 2026 and has said it is working to complete the remaining delayed reports, which could ease a key overhang.

What Could Prevent the Target From Being Reached

  • Delisting risk. Nasdaq issued a Staff Delisting Determination in October 2026 over delayed filings; the company has appealed, but the outcome is uncertain.
  • Reporting backlog. Quarterly reports for the first three quarters of 2026 remained outstanding, with additional time needed for accounting review.
  • Illiquidity. Wide bid-ask spreads and modest float make the stock susceptible to sharp, sentiment-driven swings.
  • Negative rating signals. Some rating services have maintained a sell-equivalent stance, reflecting the compliance and execution concerns.

Technical Levels and Market Structure

The stock is in a longer-term downtrend, trading well below its 50-day (near $1.64) and 200-day (near $1.87) moving averages. The 52-week low near $1.01 is the key downside support level, with the recent trading range roughly $1.10–$1.40. Above $1.50, the moving averages and the $2.00 psychological level form successive resistance zones, while the 52-week high near $3.22 marks the upper bound of recent memory. For a move toward $1.50 to hold, the shares would likely need to reclaim and hold the mid-$1.30s as new support.

Time Horizon and What Investors Should Monitor

In the absence of formal analyst targets, no standard 12-month research horizon applies to the $1.50 scenario. Investors should watch the Nasdaq Hearings Panel process and any filings completing the delayed quarterly reports, which could materially shift the outlook in either direction. Upcoming earnings and revenue results, dividend decisions, and any guidance on the insurance segments are also relevant. Because this is a balance-sheet story, changes in reported book value and reserve or actuarial adjustments in the life-and-health segment deserve particular attention.

Final Assessment

Can Atlantic American (AAME) stock reach $1.50? The figure is attainable on paper given a book value near $5.90 and a price near $1.20, but it hinges on a re-rating that the market has so far been unwilling to grant. The central supports are the deep valuation discount, improved 2025 profitability, and a substantial cash position; the principal obstacles are the unresolved Nasdaq delisting process, a backlog of delayed filings, and thin liquidity. With no credible analyst consensus to lean on, investors should treat $1.50 as a valuation scenario requiring confirmation of restored reporting and compliance, not as a forecast or a recommendation.

AI Daily Buy/Sell Signals

In my own analysis, I often rely on Tickeron's AI Daily Buy/Sell Signals to track momentum shifts in thinly traded names like this. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. For a volatile micro-cap such as AAME, these signals provide an efficient way to spot changing trends and supplement independent research without needing to review every chart manually.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AAME

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


AAME's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for AAME turned positive on November 10, 2026. Looking at past instances where AAME's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on AAME as a result. In 79 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

Following a +10.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where AAME advanced for three days, in 160 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Bearish Trend Analysis

The 10-day RSI Indicator for AAME moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 56 cases where AAME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

AAME moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AAME crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AAME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

AAME broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AAME's P/B Ratio (0.207) is slightly lower than the industry average of (1.337). P/E Ratio (4.826) is within average values for comparable stocks, (19.773). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (0.463). Dividend Yield (0.072) settles around the average of (0.047) among similar stocks. AAME's P/S Ratio (0.134) is slightly lower than the industry average of (1.303).

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. AAME’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AAME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.

Notable companies

The most notable companies in this group are MetLife (NYSE:MET), Prudential Financial (NYSE:PRU), Lincoln National Corp (NYSE:LNC), Genworth Financial (NYSE:GNW).

Industry description

Life insurance companies mainly sell policies that pay a death benefit as a lump sum upon the death of the insured to their beneficiaries. Life insurance policies may be sold as term life, (which guarantees payment of a stated death benefit and expires at the end of a specified term) or permanent /typically whole life (which is more expensive but lasts a lifetime and carries a cash accumulation component). Life insurance firms may also sell long-term disability policies that help to replace the insured individual’s income if they become sick or disabled. Health insurance, on the other hand, helps pay for medical expenses. Anthem, Inc., MetLife, Inc. and Aflac Incorporated are some of the largest U.S. companies in this industry.

Market Cap

The average market capitalization across the Life/Health Insurance Industry is 18.5B. The market cap for tickers in the group ranges from 228.36K to 140.68B. CILJF holds the highest valuation in this group at 140.68B. The lowest valued company is GWGHQ at 228.36K.

High and low price notable news

The average weekly price growth across all stocks in the Life/Health Insurance Industry was -7%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -9%. SNFCA experienced the highest price growth at 0%, while ABX experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Life/Health Insurance Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 65
Price Growth Rating: 56
SMR Rating: 91
Profit Risk Rating: 61
Seasonality Score: 9 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of life, health, property and casualty insurance services

Industry LifeHealthInsurance

Industry
Multi Line Insurance
Address
4370 Peachtree Road, North East
Phone
+1 404 266-5500
Employees
156
Web
https://www.atlam.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.